In contrast, loss of GPX4 function results in selective ferroptotic death of drug-tolerant persister cells and prevents tumor relapse in vivo, as demonstrated in breast cancer, non-small cell lung cancer, and ovarian cancer models [46]. This evidence concerns the gene GPX4 and neoplasm.